Lupin Q3 earnings surge; receives "A-" leadership rating

** Lupin (BSE: 500257) reported strong Q3 FY2025 earnings, highlighted by a five-year high EBITDA margin of 24.3%, driven by growth across key markets and improved profitability. The company expects to maintain EBITDA margins in the range of 22%-23% for the current fiscal year. Lupin’s US business achieved a five-year revenue high, while the India formulations business grew by 9.1%. R&D spending remains a priority, with a planned increase in Q4 focused on complex generics, respiratory products, and injectables. Concurrent with its financial performance, Lupin announced receiving an "A-" leadership rating from CDP for its climate change and water security initiatives. This reflects Lupin's commitment to environmental transparency, sustainable practices, and setting new standards in the pharmaceutical industry. The company's sustainability framework prioritizes environmental stewardship, employee well-being, and patient-centric innovation.